KBY Biotech Indexv0.0.34
Search
← Pipeline|Darazasiran

Darazasiran

Phase 3
NUV-8308
By Nuvation Bio
Source: Trial-derived·Trials: 1
Modality
Gene Therapy
MOA
CGRPant
Target
B7-H3
Pathway
NF-κB
AngelmanUrothelial CaRett
Development Pipeline
Preclinical
~Aug 2019
→ ~Nov 2020
Phase 1
~Feb 2021
→ ~May 2022
Phase 2
~Aug 2022
→ ~Nov 2023
Phase 3
Feb 2024
Phase 3Current
NCT07051515
1,061 pts·Rett
2024-02→TBD·Terminated
1,061 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P3
Termina…
Terminated|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT07051515Phase 3RettTerminated1061EFS
Competitors (10)
DrugCompanyPhaseTargetMOA
TerafutibatinibPfizerPhase 1/2CD38CGRPant
SotovorutinibPfizerApprovedAβCGRPant
LLY-4358Eli LillyPhase 3B7-H3CFTRmod
CeviglumideRocheNDA/BLAB7-H3CD47i
ABB-3060AbbViePhase 2LAG-3CGRPant
SNY-9600SanofiNDA/BLAB7-H3PD-L1i
SNY-8628SanofiNDA/BLAB7-H3TYK2i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
NVO-7840Novo NordiskPhase 2/3B7-H3GLP-1ag
NVO-7872Novo NordiskNDA/BLAB7-H3BTKi